This gut-level glucose gating represents a previously underappreciated peripheral arm of orexin action, offering a novel therapeutic avenue, such as OX2R agonists, to slow carbohydrate absorption and improve glycemic control in diabetes, akin to α-glucosidase inhibitors but via a neuropeptide mechanism. Here, HCRTR2 is linked to diabetes mellitus.